Sign in or create an account to add this stock to your watchlist.
About Pacific Biosciences of California (NASDAQ:PACB)
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:PACB
CUSIP69404D10
Phone650-521-8000
Debt
Debt-to-Equity Ratio0.14
Current Ratio4.64
Quick Ratio3.60
Price-To-Earnings
Trailing P/E Ratio-2.91
Forward P/E Ratio-4.02
P/E GrowthN/A
Sales & Book Value
Annual Sales$93.47 million
Price / Sales3.57
Cash FlowN/A
Price / CashN/A
Book Value$0.78 per share
Price / Book3.24
Profitability
EPS (Most Recent Fiscal Year)($0.87)
Net Income$-92,180,000.00
Net Margins-105.22%
Return on Equity-91.11%
Return on Assets-58.10%
Miscellaneous
Employees456
Outstanding Shares131,880,000
Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions
What is Pacific Biosciences of California's stock symbol?
Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."
How were Pacific Biosciences of California's earnings last quarter?
Pacific Biosciences of California (NASDAQ:PACB) issued its earnings results on Wednesday, May, 2nd. The biotechnology company reported ($0.20) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.01. The biotechnology company had revenue of $19.40 million for the quarter, compared to analyst estimates of $23.97 million. Pacific Biosciences of California had a negative return on equity of 91.11% and a negative net margin of 105.22%. The firm's revenue was down 22.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.26) EPS. View Pacific Biosciences of California's Earnings History.
When is Pacific Biosciences of California's next earnings date?
What price target have analysts set for PACB?
2 brokers have issued 12-month target prices for Pacific Biosciences of California's stock. Their forecasts range from $4.00 to $6.80. On average, they anticipate Pacific Biosciences of California's stock price to reach $5.40 in the next twelve months. View Analyst Ratings for Pacific Biosciences of California.
Who are some of Pacific Biosciences of California's key competitors?
Some companies that are related to Pacific Biosciences of California include Accelerate Diagnostics (AXDX), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), pSivida (EYPT), HTG Molecular Diagnostics (HTGM), Aethlon Medical (AEMD), Arrayit Corp common stock (ARYC), Precipio (PRPO), Pressure Biosciences (PBIO), Scientific Industries (SCND) and PositiveID (PSID).
Who are Pacific Biosciences of California's key executives?
Pacific Biosciences of California's management team includes the folowing people:
- Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 69)
- Ms. Susan K. Barnes, Sr. VP & CFO (Age 64)
- Mr. James Michael Phillips, Sr. VP of R&D (Age 67)
- Mr. Kevin P. Corcoran, Sr. VP of Market Devel. (Age 59)
- Ms. Kathy P. Ordoñez, Chief Commercial Officer, Exec. VP & Director (Age 67)
Has Pacific Biosciences of California been receiving favorable news coverage?
Headlines about PACB stock have trended somewhat negative this week, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Pacific Biosciences of California earned a media sentiment score of -0.02 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 47.35 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Pacific Biosciences of California's major shareholders?
Pacific Biosciences of California's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.67%), Blackstone Group L.P. (3.13%), Point72 Asset Management L.P. (1.59%), Northern Trust Corp (1.00%), Trellus Management Company LLC (0.59%) and Schwab Charles Investment Management Inc. (0.39%). View Institutional Ownership Trends for Pacific Biosciences of California.
Which institutional investors are selling Pacific Biosciences of California stock?
Which institutional investors are buying Pacific Biosciences of California stock?
PACB stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Blackstone Group L.P., BlackRock Inc., Citadel Advisors LLC, Millennium Management LLC, UBS Group AG, Trellus Management Company LLC and Northern Trust Corp. View Insider Buying and Selling for Pacific Biosciences of California.
How do I buy shares of Pacific Biosciences of California?
Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pacific Biosciences of California's stock price today?
One share of PACB stock can currently be purchased for approximately $2.53.
How big of a company is Pacific Biosciences of California?
Pacific Biosciences of California has a market capitalization of $333.65 million and generates $93.47 million in revenue each year. The biotechnology company earns $-92,180,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. Pacific Biosciences of California employs 456 workers across the globe.
How can I contact Pacific Biosciences of California?
Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]
MarketBeat Community Rating for Pacific Biosciences of California (PACB)
MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote "Outperform" if you believe PACB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PACB will underperform the S&P 500 over the long term. You may vote once every thirty days.
Pacific Biosciences of California (NASDAQ:PACB) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Pacific Biosciences of California in the last 12 months. Their average twelve-month price target is $5.40, suggesting that the stock has a possible upside of 113.44%. The high price target for PACB is $6.80 and the low price target for PACB is $4.00. There are currently 2 hold ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.00 | 2.33 | 2.33 | 2.33 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $5.40 | $6.2667 | $6.2667 | $6.2667 |
| Price Target Upside: | 113.44% upside | 55.50% upside | 55.50% upside | 55.50% upside |
Pacific Biosciences of California (NASDAQ:PACB) Consensus Price Target History
Pacific Biosciences of California (NASDAQ:PACB) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
Pacific Biosciences of California (NASDAQ:PACB) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Pacific Biosciences of California (NASDAQ PACB) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 13.40%
Institutional Ownership Percentage: 70.49%
Pacific Biosciences of California (NASDAQ PACB) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/28/2016 | James Michael Phillips | SVP | Sell | 20,000 | $8.44 | $168,800.00 | 201,449 |  |
| 7/29/2016 | James Michael Phillips | SVP | Sell | 20,000 | $8.45 | $169,000.00 | 198,949 | |
| 4/25/2016 | James Michael Phillips | SVP | Sell | 20,000 | $10.29 | $205,800.00 | 201,449 | |
| 3/2/2015 | Brian B Dow | VP | Buy | 2,503 | $4.91 | $12,289.73 | | |
| 3/2/2015 | Kevin P Corcoran | SVP | Buy | 2,816 | $4.91 | $13,826.56 | | |
| 8/19/2014 | William W Ericson | Director | Buy | 39,299 | $5.14 | $201,996.86 | | |
| 8/18/2014 | William W Ericson | Director | Buy | 135,155 | $5.09 | $687,938.95 | | |
| 8/14/2014 | William W Ericson | Director | Buy | 77,822 | $5.00 | $389,110.00 | | |
| 8/13/2014 | William W Ericson | Director | Buy | 29,435 | $4.93 | $145,114.55 | | |
| 8/12/2014 | William W Ericson | Director | Buy | 123,423 | $4.89 | $603,538.47 | | |
| 12/12/2013 | Michael Hunkapiller | CEO | Buy | 100,000 | $4.13 | $413,000.00 | 1,800,000 | |
| 11/21/2013 | Michael Hunkapiller | CEO | Buy | 200,000 | $3.61 | $722,000.00 | 1,700,000 | |
| 12/3/2012 | Michael Hunkapiller | CEO | Buy | 154,100 | $1.75 | $269,675.00 | | |
| 11/29/2012 | Michael Hunkapiller | CEO | Buy | 242,200 | $1.68 | $406,896.00 | | |
| 11/26/2012 | Michael Hunkapiller | CEO | Buy | 186,400 | $1.44 | $268,416.00 | | |
| 11/20/2012 | Michael Hunkapiller | CEO | Buy | 155,000 | $1.27 | $196,850.00 | | |
| 11/16/2012 | Michael Hunkapiller | CEO | Buy | 262,300 | $1.16 | $304,268.00 | | |
| 8/7/2012 | Michael Hunkapiller | CEO | Buy | 400,000 | $1.75 | $700,000.00 | | |
(Data available from 1/1/2013 forward)
Pacific Biosciences of California (NASDAQ PACB) News Headlines
| Source: |
|
Pacific Biosciences of California (NASDAQ:PACB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Pacific Biosciences of California (NASDAQ:PACB) Income Statement, Balance Sheet and Cash Flow Statement
Pacific Biosciences of California (NASDAQ PACB) Stock Chart for Sunday, May, 27, 2018
Loading chart…
